GENE ONLINE|News &
Opinion
Blog

2022-08-24| M&A

Alcon Acquires Aerie For $770 Million, Adding Eye Drops To Portfolio

by Joy Lin
Share To

Eye care veteran Alcon is buying Aerie Pharmaceuticals for an estimated $770 million, the company announced Monday. The acquisition will add Aerie’s commercial eye drops Rocklatan and Rhopressa as well as a pipeline of clinical and preclinical candidates to Alcon’s growing ophthalmology portfolio. 

The purchase price of $15.25 per share represents a 37% premium to Aerie’s last closing price. Alcon is funding the transaction through short-term and long-term debt, and expects the deal to close in Q4 of 2022. 

Alcon has an extensive history spanning 75 years selling eye care products. The company was acquired by Novartis for more than $50 billion in 2011 before being spun off in April 2019 to become a separately traded standalone company. 

Related article: Bristol Myers Squibb Completes Third Largest Acquisition of 2022

Rocklatan, Rhopressa And Other Eye Care Products

The Aerie acquisition gives Alcon Rocklatan (netarsudil and latanoprost ophthalmic solution 0.02%/0.005%), a treatment approved for reducing elevated eye pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan is a fixed dose combination of netarsudil, a Rho kinase inhibitor, and latanoprost, a prostaglandin F2α analogue. 

Rhopressa (netarsudil ophthalmic solution 0.02%), the second commercial product in the deal, is also indicated to treat glaucoma and ocular hypertension. The ex-US marketing rights for both Rhopressa and Rocklatan have been licensed to Santen, a Japanese pharma. 

Besides the approved eye drops, Alcon will also take over the development of Aerie’s Phase 3 asset for dry eye, AR-15512, as well as several investigational ophthalmology candidates. 

Alcon’s Vision Broadens In Eye Care Space 

Alcon has been busy making acquisitions in the eye drop space. The company purchased US commercialization rights to eye pressure medication Simbrinza from Novartis for $355 million last year. 

This May, Alcon bought corticosteroid anti-inflammatory medicines Eysuvis and Inveltys from Kala Pharmaceutical for $60 million upfront. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Medtech Superwomen Rewriting Healthcare’s Future & Redefining Its Possibilities
2025-03-04
LATEST
CRISPR Makes History with First One-of-a-Kind Gene Therapy for Infant
2025-05-16
VintaBio Showcases High-Yield VintaProcess Platform for Gene Therapy Vector Production at ASGCT 2025
2025-05-15
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14
Health Secretary Kennedy Retracts Parts of Agency Reorganization Plan During Combative Congressional Hearing
2025-05-14
EVENT
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top